This study would be improved if the clinical cohort was large enough to accommodate more SQSTM1 polymorphisms for genetic analysis and if the CSF p62 levels of patients with AD in ADNI were available for the correlation analysis with SQSTM1 polymorphisms. This evidence concerns the gene SQSTM1 and Alzheimer disease.